Cyclin-Dependent Kinase Inhibitor p16
"Cyclin-Dependent Kinase Inhibitor p16" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A product of the p16 tumor suppressor gene (GENES, P16). It is also called INK4 or INK4A because it is the prototype member of the INK4 CYCLIN-DEPENDENT KINASE INHIBITORS. This protein is produced from the alpha mRNA transcript of the p16 gene. The other gene product, produced from the alternatively spliced beta transcript, is TUMOR SUPPRESSOR PROTEIN P14ARF. Both p16 gene products have tumor suppressor functions.
Descriptor ID |
D019941
|
MeSH Number(s) |
D12.644.360.225.200 D12.776.167.187.200 D12.776.476.225.200 D12.776.624.776.355.200
|
Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p16- Cyclin-Dependent Kinase Inhibitor p16
- Cyclin Dependent Kinase Inhibitor p16
- CDKN2 Protein
- CDKN2A Protein
- MTS1 Protein
- p16INK4 Protein
- p16(INK4A)
- INK4A Protein
- Protein, INK4A
- Cyclin-Dependent Kinase Inhibitor-2A
- Cyclin Dependent Kinase Inhibitor 2A
- Multiple Tumor Suppressor-1
- Multiple Tumor Suppressor 1
- Cdk4-Associated Protein p16
- Cdk4 Associated Protein p16
- p16INK4A Protein
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p16".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p16".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p16" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 0 | 7 | 7 |
1996 | 1 | 4 | 5 |
1997 | 2 | 5 | 7 |
1998 | 5 | 9 | 14 |
1999 | 8 | 5 | 13 |
2000 | 2 | 3 | 5 |
2001 | 7 | 11 | 18 |
2002 | 7 | 3 | 10 |
2003 | 7 | 11 | 18 |
2004 | 8 | 5 | 13 |
2005 | 5 | 4 | 9 |
2006 | 7 | 5 | 12 |
2007 | 8 | 4 | 12 |
2008 | 4 | 6 | 10 |
2009 | 7 | 7 | 14 |
2010 | 3 | 5 | 8 |
2011 | 2 | 11 | 13 |
2012 | 1 | 6 | 7 |
2013 | 5 | 9 | 14 |
2014 | 7 | 5 | 12 |
2015 | 5 | 4 | 9 |
2016 | 5 | 5 | 10 |
2017 | 1 | 4 | 5 |
2018 | 4 | 4 | 8 |
2019 | 4 | 5 | 9 |
2020 | 1 | 0 | 1 |
2021 | 3 | 4 | 7 |
2022 | 1 | 2 | 3 |
2023 | 0 | 1 | 1 |
2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p16" by people in Profiles.
-
Dietary Folate and Cofactors Accelerate Age-dependent p16 Epimutation to Promote Intestinal Tumorigenesis. Cancer Res Commun. 2024 01 19; 4(1):164-169.
-
Even heterozygous loss of CDKN2A/B greatly accelerates recurrence in aggressive meningioma. Acta Neuropathol. 2023 04; 145(4):501-503.
-
Bmi1 suppresses protein synthesis and promotes proteostasis in hematopoietic stem cells. Genes Dev. 2022 08 01; 36(15-16):887-900.
-
p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Res. 2022 03 01; 82(5):916-928.
-
Oropharyngeal cancer outcomes correlate with p16 status, multinucleation and immune infiltration. Mod Pathol. 2022 08; 35(8):1045-1054.
-
Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022 01 10; 40(2):138-149.
-
Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma. Ann Thorac Surg. 2022 11; 114(5):1842-1852.
-
Epigenetic and senescence markers indicate an accelerated ageing-like state in women with preeclamptic pregnancies. EBioMedicine. 2021 Aug; 70:103536.
-
Locoregional Recurrence in p16-Positive Oropharyngeal Squamous Cell Carcinoma After TORS. Laryngoscope. 2021 12; 131(12):E2865-E2873.
-
mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK. Cancer Res. 2021 06 15; 81(12):3174-3186.